Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of ...

Serplulimab significantly improved event-free survival in gastric cancer, showing potential as a neoadjuvant/adjuvant monotherapy. The combination with chemotherapy achieved a pathologic complete ...

Watch parts 1, 2, and 3 of our conversation with Dr Collins.

FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data ...

Watch parts 1 and 2 of our conversation with Dr Collins.

Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin. With the 2025 European Society of Medical Oncology (ESMO) Congress starting on ...

“Research has shown that Medicaid expansion can increase cancer screening prevalence, early-stage diagnosis, short-term ...

Beyond this study population, there are ongoing randomized trials evaluating NBTXR3 for definitive treatment of HNSCC, including a trial for cisplatin-ineligible patients, as well as a planned study ...

Orphan drug designation provides benefits such as tax credits, PDUFA fee waivers, and 7 years of market exclusivity upon ...

mRNA-4359 combined with pembrolizumab achieved a 24% ORR and 67% efficacy in PD-L1 positive melanoma patients. The study ...

Tagraxofusp demonstrated a manageable safety profile but limited efficacy in CMML patients, with stable disease as the best ...

Acalabrutinib (Calquence) yielded high efficacy and a manageable safety profile for the treatment of chronic lymphocytic ...